DUBLIN--(BUSINESS WIRE)--The "Tinnitus - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
The publisher's, "Tinnitus - Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Tinnitus pipeline landscape.
A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tinnitus R&D. The therapies under development are focused on novel approaches to treat/improve Tinnitus.
Tinnitus Emerging Drugs Chapters
This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tinnitus Emerging Drugs
AM-101: Auris Medical
AM-101 is an NMDA receptor antagonist that is being developed for treatment of acute inner ear tinnitus. The NMDA (N-methyl-D-aspartate) receptor is a glutamate receptor on the neuron leading to the auditory cortex that is communicated to by the hair cells of the inner ear. The drug is in Phase III clinical development for the treatment of Tinnitus.
OTO-313: Otonomy
OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. It is believed that gacyclidine can reduce the severity of tinnitus symptoms following cochlear injury by decreasing the over-activation of damaged auditory nerve fibers in the cochlea and their connections. OTO-313 utilizes a novel, patent-protected formulation technology to provide several weeks of gacyclidine drug exposure in the inner ear following a single intratympanic injection. In 2020, positive results were reported from a Phase I/II trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity. A Phase II trial is currently underway with results expected in mid-2022. In November 2014, Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus.
Phases
The publisher's report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Tinnitus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Tinnitus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.
Tinnitus Report Insights
- Tinnitus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Tinnitus Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Companies Mentioned
- Otonomy
- Auris Medical
- Gateway Biotechnology
- Cognosetta
- Knopp Biosciences
- Otologic Pharmaceutics
- Decibel therapeutics
- AudioCure Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jv0584
